Moderna Therapeutics has raised another $500 million, which values the biotechnology startup at about $7.5 billion, PitchBook first reported. The cash comes from existing investors as well as a "global syndicate that stretches from the Middle East to Europe and on to China," EndPoints reports.
Why it matters: Moderna's next step likely is going public, which would make it the most valuable biotech public offering ever.
Go deeper: STAT profiled Moderna, which is using technology to modify human cells to fight off an array of diseases.